
LFCR Stock Forecast & Price Target
LFCR Analyst Ratings
Bulls say
Lifecore Biomedical is projected to demonstrate significant financial growth with EBITDA expected to increase from $25.1 million, representing a 16.8% margin in FY26, to $27.3 million, indicating a 19.1% margin in FY27. The company also reported a positive shift in free cash flow, expected to grow from $5.1 million in FY26 to $6.0 million in FY27. These metrics highlight Lifecore's enhanced profitability and efficient cash management, supporting a positive outlook for the company’s financial performance.
Bears say
Lifecore Biomedical Inc faces challenges due to the anticipated market growth for the fill/finish segment being slightly below expectations, influenced by the inclusion of small molecule injectables, which dampens revenue potential. The company is projected to experience a high leverage ratio alongside a lack of meaningful revenue growth until calendar year 2027, raising concerns about its financial health and investment appeal. Consequently, this combination of factors supports a negative outlook, suggesting that a discount to peer valuations is justified.
This aggregate rating is based on analysts' research of Lifecore Biomedical Inc and is not a guaranteed prediction by Public.com or investment advice.
LFCR Analyst Forecast & Price Prediction
Start investing in LFCR
Order type
Buy in
Order amount
Est. shares
0 shares